Reply

Ju Dong Yang^{1

2

3

4}, Kristin C Mara⁵, Gregory J Gores⁴, Lewis R Roberts⁴

Affiliations

¹ Division of Digestive and Liver Diseases, Cedars-Sinai Medical Center, Los Angeles, CA.
² Comprehensive Transplant Center, Cedars Sinai Medical Center, Los Angeles, CA.
³ Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, CA.
⁴ Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, Rochester, MN.
⁵ Department of Health Science Research, Mayo Clinic College of Medicine and Science, Rochester, MN.

Comment

Ju Dong Yang et al. Hepatology. 2020 Jul.

. 2020 Jul;72(1):364-365.

doi: 10.1002/hep.31098.

Ju Dong Yang^{1

2

3

4}, Kristin C Mara⁵, Gregory J Gores⁴, Lewis R Roberts⁴

¹ Division of Digestive and Liver Diseases, Cedars-Sinai Medical Center, Los Angeles, CA.
² Comprehensive Transplant Center, Cedars Sinai Medical Center, Los Angeles, CA.
³ Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, CA.
⁴ Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, Rochester, MN.
⁵ Department of Health Science Research, Mayo Clinic College of Medicine and Science, Rochester, MN.

No abstract available

Comment on

Diabetes Is Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Cirrhosis From Nonalcoholic Fatty Liver Disease.
Yang JD, Ahmed F, Mara KC, Addissie BD, Allen AM, Gores GJ, Roberts LR. Yang JD, et al. Hepatology. 2020 Mar;71(3):907-916. doi: 10.1002/hep.30858. Epub 2019 Oct 21. Hepatology. 2020. PMID: 31309602 Free PMC article.
Letter to the Editor: The Association Between Diabetes and Hepatocellular Carcinoma in Patients With Cirrhosis Caused by Nonalcoholic Fatty Liver Disease.
Tantai X, Liu N, Wang J. Tantai X, et al. Hepatology. 2020 Jul;72(1):363-364. doi: 10.1002/hep.31099. Hepatology. 2020. PMID: 31904864 No abstract available.

1. Yang JD, Ahmed F, Mara KC, Addissie BD, Allen AM, Gores GJ, et al. Diabetes is associated with increased risk of hepatocellular carcinoma in cirrhosis patients with nonalcoholic fatty liver disease. Hepatology 2019 Jul 15. https://doi.org/10.1002/hep.30858. [Epub ahead of print]
1. Simon TG, Ma Y, Ludvigsson JF, Chong DQ, Giovannucci EL, Fuchs CS, et al. Association between aspirin use and risk of hepatocellular carcinoma. JAMA Oncol 2018;4:1683-1690.
1. Lee TY, Hsu YC, Tseng HC, Yu SH, Lin JT, Wu MS, et al. Association of daily aspirin therapy with risk of hepatocellular carcinoma in patients with chronic hepatitis B. JAMA Intern Med 2019;179:633-640.
1. Li Z, Li Y, Li X, Zhang L, Zhao N, Du H, et al. Statins on hepatocellular carcinoma risk in hepatitis B or C patients protocol for a systematic review and meta-analysis. Medicine (Baltimore) 2018;97:e11950.
1. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 2019;16:589-604.